1. Home
  2. MNRO vs ANL Comparison

MNRO vs ANL Comparison

Compare MNRO & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monro Inc.

MNRO

Monro Inc.

HOLD

Current Price

$11.71

Market Cap

545.6M

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$13.05

Market Cap

611.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNRO
ANL
Founded
1957
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Automotive Aftermarket
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
545.6M
611.1M
IPO Year
1994
2022

Fundamental Metrics

Financial Performance
Metric
MNRO
ANL
Price
$11.71
$13.05
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$16.00
$20.00
AVG Volume (30 Days)
946.9K
213.3K
Earning Date
05-27-2026
04-10-2026
Dividend Yield
6.69%
N/A
EPS Growth
113.64
N/A
EPS
0.03
N/A
Revenue
$1,157,176,000.00
N/A
Revenue This Year
N/A
$36.02
Revenue Next Year
$1.59
N/A
P/E Ratio
$424.33
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.16
$0.88
52 Week High
$23.91
$17.25

Technical Indicators

Market Signals
Indicator
MNRO
ANL
Relative Strength Index (RSI) 28.55 55.67
Support Level N/A $12.41
Resistance Level $18.32 $13.29
Average True Range (ATR) 0.83 1.08
MACD -0.38 0.04
Stochastic Oscillator 0.70 44.83

Price Performance

Historical Comparison
MNRO
ANL

About MNRO Monro Inc.

Monro Inc is an operator of retail tire and automotive repair stores in the United States. The company offers replacement tires and tire related services, automotive undercar repair services, and a broad range of routine maintenance services, on passenger cars, light trucks, and vans. It also provides other products and services for brakes; mufflers and exhaust systems; and steering, drive train, suspension, and wheel alignment.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: